

Patient Name

DOB MRN

Physician CSN

Physician's Orders DENOSUMAB (PROLIA) - ADULT, OUTPATIENT, COREWELL HEALTH INFUSION CENTER Page 1 to 3

Defaults for orders not other		OW:					
☐ Interval: Every 18							
□ Interval:							
Duration:							
☐ Until date:							
□ 1 year	4 .						
□# of Treatn	nents						
Anticipated Infusion Date ICD 10 Code with Description							
Height	_(cm) Weight	(kg) Allergies					
Site of Service							
☐ CH Blodgett (GR)	☐ CH Helen De	eVos (GR)	☐ CH Ludington	☐ CH Reed City			
☐ CH Gerber	☐ CH Lemmen	Holton (GR)	☐ CH Pennock	☐ CH Zeeland			
☐ CH Greenville							
Provider Specialty							
☐ Allergy/Immunology	☐ Infectious	Disease	☐ OB/GYN	☐ Rheumatology			
□ Cardiology		ed/Family Practice		☐ Surgery			
☐ Gastroenterology				☐ Urology			
☐ Genetics ☐ Neurology			☐ Pulmonary	☐ Wound Care			
Appointment Requests							
✓ Infusion Appointment Request Status: Future, Expected: S, Expires: S+366, Sched. Tolerance: Schedule appointment at most 3 days before or at most 3 days after, Injection and possible labs							
Safety Parameters and S	pecial instructions	5					
ONC SAFETY P INSTRUCTION Renal function (se within 3 months of	NS 1	SPECIAL Im calcium must be resulte	ed				
ONC SAFETY PARAMETERS AND SPECIAL INSTRUCTIONS 5 DENOSUMAB (PROLIA):							
Ensure adequate calcium and vitamin D intake to prevent or treat hypocalcemia.							
MEDICATION GUIDE: An FDA-approved patient medication guide, which is available with the product information and should be dispensed with this medication. Https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/125320s181lbl.pdf#page=27							
Monitor serum calcium levels regularly throughout treatment due to risk for hypocalcemia.							



DENOSUMAB (PROLIA) - ADULT, OUTPATIENT, COREWELL HEALTH INFUSION CENTER (CONTINUED) Page 2 to 3

Patient Name
DOB
MRN
Physician
CCN

Nursing Orders

Interval

Duration

Hypersensitivity Reaction Adult Oncology Protocol

Until discontinued

Routine, Until discontinued Starting when released for 24 hours HYPERSENSITIVITY REACTIONS:

Discontinue the medication infusion immediately.

Activate emergency response for severe or rapidly progressing symptoms. Where available consider calling RAP and have crash cart available. Call 911 or code team (if applicable) as needed for an absence of pulse and respirations. Refer to site specific emergency response policy.

Stay with patient until symptoms have resolved.

Initiate/Continue Oxygen to maintain SpO2 greater than 90% and discontinue Oxygen Therapy to maintain SpO2 above 90%

For severe or rapidly progressing hypersensitivity reaction symptoms, monitor vital signs and pulse oximeter readings every 2 to 5 minutes until the patient is stable and symptoms resolve.

Document medication infusing and approximate dose received at time of reaction in the patient medical record. Document allergy to medication attributed with causing reaction in patient medical record. Complete Adverse Drug Reaction form per Pharmacy Clinical Policy.

Labs



- Comprehensive Metabolic Panel (CMP)
 - Status: Future, Expected: S, Expires: S+184, URGENT, Clinic Collect, Blood, Blood, Venous
- Complete Blood Count w/Differential

Status: Future, Expected: S, Expires: S+184, URGENT, Clinic Collect, Blood, Blood, Venous

- Magnesium, Blood Level
 - Status: Future, Expected: S, Expires: S+365, URGENT, Clinic Collect, Blood, Blood, Venous
- Phosphorus, Blood Level

Status: Future, Expected: S, Expires: S+365, URGENT, Clinic Collect, Blood, Blood, Venous

- Rule Based Evaluation For Monthly **Pregnancy Test Before Chemotherapy** Cycles
 - ONC PROVIDER REMINDER 28

Pregnancy test required

- * Female, aged 12 to 60 years
- * Uterus is still intact

Beta Human Chorionic Gonadotropin (hCG) Quantitative

Status: Future, Expected: S, Expires: S+365, URGENT, Clinic Collect, Blood, Blood, Venous





Patient Name
DOB
MRN
Physician
CSN

Additional Lab Orders						
	Interval	Duration				
□ Labs: ————	□ Every days □ Once	☐ Until date: ☐ 1 year ☐# of treatment				
ONC MONITORING AND HOLD PARAMETERS 3 May proceed with treatment if patient does not report any symptoms of jaw or dental pain.						
Medications						
denosumab (PROLIA) inju 60 mg, Subcutaneous, Once,	ection 60 mg					
ou mg, Subcutaneous, Once,	, Starting S, Fur i Duses					

Telephone order/Verbal order documented and read-back completed. Practitioner's initials _

NOTE: Unless Order is written DAW (dispense as written), medication may be supplied which is a generic equivalent by nonproprietary name.

TRANSCRIBED:		VALIDATED:		ORDERED:				
	TIME	DATE	TIME	DATE	TIME	DATE	Pager #	
				R.N.		Physician		Physician
		Sign		Sign		Print		Sign

EPIC VERSION DATE: 12/8/23